Anas Younes

发表

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

Marilyn M. Li, Somak Roy, Marina N Nikiforova, 2017, The Journal of molecular diagnostics : JMD.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Scott E Smith, Bruce D Cheson, Andreas Engert, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Sang Hoon Lee, Wen-Kai Weng, Mohammad Luqman, 2008, Blood.

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

Nancy Whiting, R. Advani, A. Younes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Coexpression of CD40 and CD40 ligand in B‐cell lymphoma cells

K. Kliche, M. Andreeff, F. Cabanillas, 1998, British journal of haematology.

A novel immunomodulatory and molecularly targeted strategy for refractory Hodgkin's lymphoma

Vivek Subbiah, Mary F. McGuire, Robert E. Brown, 2013, Oncotarget.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

John P Leonard, J. Leonard, A. Younes, 2010, The New England journal of medicine.

Precision therapy for lymphoma—current state and future directions

A. Intlekofer, A. Younes, Anas Younes, 2014, Nature Reviews Clinical Oncology.

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.

Scott E. Smith, Eric Lester, Theodore Karrison, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma

Andreas Engert, Arnold S. Freedman, Martin J. S. Dyer, 2014, British journal of haematology.

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

A. Younes, E. Derenzini, Anas Younes, 2011, Genome Medicine.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

James Allison, Stephen Forman, Massimo Cristofanilli, 2015, Mayo Clinic proceedings.

Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia

M. Andreeff, A. Younes, U. Consoli, 1998, British journal of haematology.

MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival.

Mamoun Younes, Georgios Georgakis, Jean Nicolas Vauthey, 2003, Blood.

Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma

Yuan Ji, Paolo Anderlini, A. Younes, 2011, British journal of haematology.

Using social media in oncology for education and patient engagement.

Robert S. Miller, A. Younes, M. Thompson, 2012, Oncology.

Experience with heat shock protein‐peptide complex 96 vaccine therapy in patients with indolent non‐Hodgkin lymphoma

Y. Oki, P. Srivastava, P. Mclaughlin, 2007, Cancer.

Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL).

Ahmet Dogan, Andrew D. Zelenetz, Heiko Schöder, 2017 .